<DOC>
	<DOCNO>NCT00435045</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Omacor ( omega-3-acid ethyl ester ) combine atorvastatin lower non-high-density lipoprotein cholesterol ( non-HDL-C ) hypertriglyceridemic subject .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Omacor , Co-Administered With Atorvastatin , Subjects With Hypertriglyceridemia</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , parallel-group study design eleven clinic visit ( one screen visit , three lead-in/baseline visit , seven treatment visit ) After 4-week diet lead-in period , subject triglyceride ( TG ) level high high range non-HDL-C level NCEP ATPIII goal randomize receive either open-label atorvastatin 10 mg per day plus double-blinded Lovaza 4g ( 4 x 1g capsule ) per day OR open-label atorvastatin 10 mg per day plus double-blinded matching placebo ( 4 corn oil capsule per day ) 8 week After initial 8-week treatment period , dose open-label atorvastatin titrate 20 mg per day ( Lovaza match placebo corn oil dose remain 4 capsule per day ) additional 4 week At Week 12 , second open-label titration 40 mg open-label atorvastatin per day maintain additional 4 week ( Lovaza match placebo corn oil dose remain 4 capsule per day )</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men woman , age 1879 year , inclusive Fasting , untreated nonhighdensity lipoprotein cholesterol ( nonHDLC ) level NCEP ATPIII goal Fasting , untreated triglyceride ( TG ) level high high range Provide write informed consent authorization protect health information disclosure Pregnancy Use lipidaltering drug stop History certain cardiovascular condition cardiac surgery within prior 6 month Body mass index 40 kg per square meter Allergy sensitivity omega3 fatty acid statin drug Poorlycontrolled condition include diabetes , hypertension , thyroid disease Certain muscle , liver , kidney , lung , gastrointestinal condition Certain medication Active cancer treat within prior 2 year ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lovaza</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Lipids</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>omega-3-acid ethyl ester</keyword>
	<keyword>Omacor</keyword>
	<keyword>Dyslipidemias</keyword>
</DOC>